Year: 2019
Type: article
Abstract: Neonates are a uniquely vulnerable population, compromised by immature physiology and critical illness if born premature. Furthermore, neonates have frequent exposures to drugs that lack adequate data on safety, efficacy, and appropriate dosing in this population. Key physiologic differences between neonates and older children and adults affect drug absorption, distribution, metabolism, and elimination. Adequate understanding and consideration of these differences is essential to ensure optimal dosing of therapeutic agents in this vulnerable population. Moreover, direct study of neonates through appropriately designed pharmacokinetic and pharmacodynamic studies can ensure the development of safe and effective therapeutics in our youngest populations of patients.
Source: American Journal of Perinatology
Institutions: Duke University, Duke Clinical Research Institute
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT), G2829770695, G3008453, Investigating polypharmacy-related adverse events in critically ill children using electronic health records and simulated drug levels, G5139652136, G6673297901, Duke CTSA (Composite), Identifying Pharmacogenomic Predictors of Methotrexate Response and Metabolite Biotransformation in JIA, Cincinnati Rheumatic Diseases Resource Center, Environmental influences on Child Health Outcomes (ECHO) Coordinating Center, Mentorship of early-career pediatricians in quantitative methods and therapeutics
OpenAlex ID: W2963803937